Adjusted earnings per share for the quarter stood at $0.62, matching the Zacks Consensus Estimate and slightly below the $0.64 reported in Q4 2024. The adjusted operating margin expanded by 30 basis points to 22.0%, despite modest currency headwinds. Net income declined 2.1% to €65 million, largely attributable to higher R&D investments aimed at accelerating growth in next-generation sample preparation platforms. Qiagen reported fourth-quarter revenue of €445 million, representing a 3.2% increase over the €431 million recorded in the year-ago period. Growth was driven by strength in its Molecular Diagnostics business, which delivered €255 million in revenue, up 5.1% year-on-year. Adjusted operating income grew 4.5% to €98 million, reflecting ongoing efficiency initiatives and favorable product mix shifts toward higher-margin consumables. Qiagen reiterated its full-year guidance for mid-single-digit organic revenue growth and adjusted EPS between $2.45 and $2.55. Management plans to increase R&D spending by approximately 10% in 2026 to support the launch of its automated liquid-handling system in the second half of the year. The company also approved a €200 million share repurchase program, to be executed over the next 12 months, underscoring confidence in long-term cash-flow generation. In Life Sciences, revenue was flat at €190 million, as new product rollouts in sample and assay technologies were offset by weaker instrument placements. The Asia-Pacific region delivered 8% revenue growth to €105 million, driven by China and Japan, while North America sales dipped 1.5% to €185 million due to inventory adjustments at large laboratory customers. Europe generated €155 million, up 2% on continued demand for oncology-focused assays.